Page 25 - Read Online

van der Ent et al. J Transl Genet Genom 2018;2:10. I https://doi.org/10.20517/jtgg.2018.09 Page 11 of 12

Establishment of an in vivo model for pediatric Ewing tumors by transplantation into NOD/scid mice. Pediatr Res 2001;49:332-41.
95. Franzius C, Hotfilder M, Poremba C, Hermann S, Schäfers K, Gabbert HE, Jürgens H, Schober O, Schäfers M, Vormoor J. Successful high-
resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl
Med Mol Imaging 2006;33:1432-41.
96. Wang YX, Mandal D, Wang S, Hughes D, Pollock RE, Lev D, Kleinerman E, Hayes-Jordan A. Inhibiting platelet-derived growth factor β
reduces Ewing’s sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo 2009;23:903-9.
97. Vormoor B, Knizia HK, Batey MA, Almeida GS, Wilson I, Dildey P, Sharma A, Blair H, Hide IG, Heidenreich O, Vormoor J, Maxwell RJ,
Bacon CM. Development of a preclinical orthotopic xenograft model of Ewing sarcoma and other human malignant bone disease using
advanced in vivo imaging. PLoS One 2014;9:e85128.
98. Goldstein SD, Hayashi M, Albert CM, Jackson KW, Loeb DM. An orthotopic xenograft model with survival hindlimb amputation allows
investigation of the effect of tumor microenvironment on sarcoma metastasis. Clin Exp Metastasis 2015;32:703-15.
99. Hong SH, Tilan JU, Galli S, Izycka-Swieszewska E, Polk T, Horton M, Mahajan A, Christian D, Jenkins S, Acree R, Connors K, Ledo
P, Lu C, Lee YC, Rodriguez O, Toretsky JA, Albanese C, Kitlinska J. High neuropeptide Y release associates with Ewing sarcoma bone
dissemination - in vivo model of site-specific metastases. Oncotarget 2015;6:7151-65.
100. Harris JC, Coburn JM, Kajdacsy-Balla A, Kaplan DL, Chiu B. Sustained delivery of vincristine inside an orthotopic mouse sarcoma model
decreases tumor growth. J Pediatr Surg 2016;51:2058-62.
101. VAN Noord RA, Thomas T, Krook M, Chukkapalli S, Hoenerhoff MJ, Dillman JR, Lawlor ER, Opipari VP, Newman EA. Tissue-directed
implantation using ultrasound visualization for development of biologically relevant metastatic tumor xenografts. In Vivo 2017;31:779-91.
102. Sirsi SR, Flexman ML, Vlachos F, Huang J, Hernandez SL, Kim HK, Johung TB, Gander JW, Reichstein AR, Lampl BS, Wang A,
Hielscher AH, Kandel JJ, Yamashiro DJ, Borden MA. Contrast ultrasound imaging for identification of early responder tumor models to
anti-angiogenic therapy. Ultrasound Med Biol 2012;38:1019-29.
103. van der Ent W, Jochemsen AG, Teunisse AF, Krens SF, Szuhai K, Spaink HP, Hogendoorn PC, Snaar-Jagalska BE. Ewing sarcoma
inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. J Pathol 2014;233:415-24.
104. El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TG, Negri GL, Somasekharan SP, Corkery DP, Tirode F, Mathers J, Khan D, Kyle AH,
Baker JH, LePard NE, McKinney S, Hajee S, Bosiljcic M, Leprivier G, Tognon CE, Minchinton AI, Bennewith KL, Delattre O, Wang Y,
Dellaire G, Berman JN, Sorensen PH. Translational activation of HIF1α by YB-1 promotes sarcoma metastasis. Cancer Cell 2015;27:682-
97.
105. Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, Dirksen U, Bouvier C, de Pinieux G, Snaar-Jagalska E,
Chavrier P, Delattre O. Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma
cells. Oncogene 2017;36:3505-14.
106. Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F, Shiozawa K, Qiao Z, Arai Y, Shibata T, Araki Y, Endo M, Kawai A,
Kondo T. Generation of novel patient-derived CIC-DUX4 sarcoma xenografts and cell lines. Sci Rep 2017;7:4712.
107. Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James AW, Igarashi K, Kawaguchi K, DeLong JC, Zhang Y, Hiroshima Y, Russell T,
Eckardt MA, Yanagawa J, Federman N, Matsuyama R, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. Effective
molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing’s sarcoma patient-
derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 2016;7:47556-64.
108. TK216 in Patients With Relapsed or Refractory Ewing Sarcoma. ClinicalTrials.gov Identifier: NCT02657005. Available from: https://
clinicaltrials.gov/ct2/show/NCT02657005 [Last accessed on 23 May 2018].
109. Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky
JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing
sarcoma. Nature 2018;555:387-91.
110. Olaparib in Adults With Recurrent/Metastatic Ewing’s Sarcoma. ClinicalTrials.gov Identifier: NCT01583543. Available from: https://
clinicaltrials.gov/ct2/show/NCT01583543 [Last accessed on 23 May 2018].
111. ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan
in Patients With Previously Treated, Incurable Ewing Sarcoma. ClinicalTrials.gov Identifier: NCT02044120. Available from: https://
clinicaltrials.gov/ct2/show/NCT02044120 [Last accessed on 23 May 2018].
112. Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM. Sensitivity of Ewing’s sarcoma to TRAIL-induced apoptosis.
Cell Death Differ 2001;8:506-14.
113. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, Koutelia N, Fisch P, Romero ME, Long L, Noellke P, Mackall CL, Niemeyer CM, Kontny
U. Interferon-gamma sensitizes resistant Ewing’s sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-
regulation of caspase-8 without altering chemosensitivity. Am J Pathol 2007;170:1917-30.
114. de Hooge AS, Berghuis D, Santos SJ, Mooiman E, Romeo S, Kummer JA, Egeler RM, van Tol MJ, Melief CJ, Hogendoorn PC,
Lankester AC. Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for
susceptibility to cytotoxic pathways. Clin Cancer Res 2007;13:206-14.
115. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PC, Egeler RM, van Tol
MJ, Schilham MW, Lankester AC. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent
pathways. Mol Immunol 2008;45:3917-25.
116. Pahl JH, Ruslan SE, Kwappenberg KM, van Ostaijen-Ten Dam MM, van Tol MJ, Lankester AC, Schilham MW. Antibody-dependent cell
lysis by NK cells is preserved after sarcoma-induced inhibition of NK cell cytotoxicity. Cancer Immunol Immunother 2013;62:1235-47.
117. Guiho R, Biteau K, Grisendi G, Taurelle J, Chatelais M, Gantier M, Heymann D, Dominici M, Redini F. TRAIL delivered by mesenchymal
stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models. Int J Cancer 2016;139:2802-11.
118. Berghuis D, Santos SJ, Baelde HJ, Taminiau AH, Egeler RM, Schilham MW, Hogendoorn PC, Lankester AC. Pro-inflammatory chemokine-
chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect